Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients.
Severe septal panniculitis in a multiple sclerosis patient treated with interferon-beta.
Validity and reliability of VO2-max measurements in persons with multiple sclerosis.
Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
CCSVI and MS: a statement from the European Society of neurosonology and cerebral hemodynamics.
Video game training enhances cognitive control in older adults.
Modeling the variability in brain morphology and lesion distribution in multiple sclerosis by deep learning.
Subcutaneous interferon β-1a in pediatric patients with multiple sclerosis: Regional differences in clinical features, disease management, and treatment outcomes in an international retrospective study.
Cannabinoid pharmacology: the first 66 years.
Oral contraceptive use and clinical outcomes in patients with multiple sclerosis.
A touch of MS: Therapeutic mislabeling.
Isolated trigeminal nerve palsy with motor involvement as a presenting manifestation of multiple sclerosis in an equatorial region - a case report.
Epitope-specific immune tolerization ameliorates experimental autoimmune encephalomyelitis.
New TYSABRI® data show earlier treatment and longer-term use result in significant reductions in MS disease activity
Segway use in individuals with multiple sclerosis.
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Serum level of interleukin-6 in Chinese patients with multiple sclerosis.
Immune modulating peptides for the treatment and suppression of multiple sclerosis.
Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
IFN-β alters neurotrophic factor expression in T cells isolated from multiple sclerosis patients - implication of novel neurotensin/NTSR1 pathway in neuroprotection.
Client-centred therapy in multiple sclerosis: More intensive diagnostic evaluation and less intensive treatment.
Innovation at RUSH
Relapses in patients treated with fingolimod after previous exposure to natalizumab.
No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis.
JC viremia in natalizumab-treated patients with multiple sclerosis.

Pages